# CMAB BioPharma (Suzhou)

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cmab-biopharma-suzhou

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Website: www.cmabbio.com
- Total disclosed funding: $72M
- Latest round: Series B (Feb 2, 2019)
- Investors on record: 8

## About

CMAB BioPharma (Suzhou) Inc., based in Suzhou, China, focuses on biopharmaceutical solutions, including the development and manufacturing of biologics for both global and domestic markets.Founded in 2017, CMAB BioPharma (Suzhou) Inc. specializes in biopharmaceuticals, particularly in the area of biologics. The company has participated in 4 deals, with the most recent funding round being a Series B of USD 34.00 mn led by CD Capital on March 17, 2021. The CEO is Yongzhong Wang, who has experience in the biopharmaceutical field. CMAB was acquired by WuXi Biologics, with the transaction expected to close in the second quarter of 2021.CMAB BioPharma specializes in advanced biotechnological solutions aimed at enhancing agricultural productivity and sustainability. The company’s core offerings include a range of bio-based products designed to improve soil health, increase crop yield, and support pest management. These products utilize natural microorganisms and nutrients to promote plant growth, enhance resistance to diseases, and optimize fertilizer use. CMAB's solutions target farmers and agricultural enterprises, particularly in North America, Europe, and parts of Asia, addressing critical challenges such as soil degradation and reliance on chemical fertilizers.CMAB BioPharma generates revenue through a structured model that includes direct sales to agricultural businesses and subscriptions for ongoing support and product replenishment. Transactions typically occur through partnerships with distributors who supply the products to end-users, including farmers and agribusinesses. The company offers various pricing plans based on the scale and type of products acquired. Flagship products, known for their efficacy and reliability, command a premium in the market, reflecting the value they provide to customers. The revenue model fosters long-term relationships with clients, ensuring a steady stream of income through repeat business and ongoing service agreements.CMAB BioPharma plans to expand its product offerings, with new products currently in development aimed at enhancing agricultural practices. The company is targeting expansion into additional markets in Europe and Asia by the end of 2022. The recent funding from the Series B round will support these initiatives, allowing CMAB to invest in R&D for product innovation and market entry strategies. The acquisition by WuXi Biologics will also provide additional resources and expertise to facilitate these growth plans.

## Funding rounds

- Series B, Feb 2, 2019 — Ming Bioventures
- Series B, Apr 2, 2018, $34M — CBC Group, CD Capital, Cormorant Capital, Tigermed, Qianhai Ark Capital
- Series A, Jan 2, 2018, $38M — CBC Group, I-Bridge Capital, BioBAY, Qianhai Ark Capital

## Investors

- CBC Group (https://capitalatlas.ai/funds/cbc-group) — Series A, Series B
- I-Bridge Capital (https://capitalatlas.ai/funds/i-bridge-capital) — Series A
- BioBAY — Series A
- Qianhai Ark Capital (https://capitalatlas.ai/funds/qianhai-ark-capital) — Series A, Series B
- CD Capital — Series B
- Cormorant Capital — Series B
- Tigermed (https://capitalatlas.ai/funds/tigermed) — Series B
- Ming Bioventures (https://capitalatlas.ai/funds/ming-bioventures) — Series B